ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-09-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and potential clinical
benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult
participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one
or two treatment regimens.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc